Making Critical Therapies More Accessible with Nasal Sprays

Nasal Drug Delivery is Gaining Traction

As scientific interest in intranasal delivery grows, so do the challenges of bringing these products to market. Success demands more than a good molecule—it requires formulation expertise, precise device integration, scalable GMP manufacturing, and strong regulatory competency.

Álvaro López, Business Development Director at Curida, offers his perspective on why nasal delivery is on the rise—and what it takes to do it right.

Get deeper insights, data, and expert perspectives.

More Resources

Join Curida at PharmaSynergy-OTC, Rome, 10- 11 September

If you’re attending and would like to discuss o...
14.05.2026

Curida Streamlines Quality Processes with AFRY

To support continued growth, remain future-read...
17.02.2026

Curida Achieves Eco Vadis Bronze Award

Over the past year, Curida has completed a doub...
13.02.2026

Controlled Drugs Manufacturing in Europe: Regulation, Nasal Delivery and CDMO Expertise

In this in-depth article, Curida examines how d...
03.02.2026

Curida Announces Strategic Partnership with Rommelag

Curida is proud to announce a new strategic par...
29.01.2026

Join Curida at euroPLX, Lisbon: 2-3 March 2026

We’re excited to join industry peers at euroPLX...
28.01.2026

Join Curida at euroPLX, Warsaw: 8-9 June 2026

We’re excited to join industry peers at euroPLX...
28.01.2026

Join Curida at CPHi WW, Milan: 6-8 October 2026

We’re excited to join industry peers at CPHi WW...
28.01.2026

Curida Launches New Website & Brand Refresh

Curida AS, a leading European Contract Developm...
10.09.2025

Nasal Sprays & Suspensions

When it comes to nasal spray drug products, the...
23.06.2025